67Cu-based NuriPro therapeutic - NUCLIDIUM
Alternative Names: 67Cu-based NuriPro™ therapeuticLatest Information Update: 04 Apr 2023
At a glance
- Originator NUCLIDIUM
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 29 Mar 2023 67Cu-based NuriPro therapeutic - NUCLIDIUM is available for licensing as of 29 Mar 2023. https://nuclidium.com/about-us/
- 28 Mar 2023 Preclinical trials in Prostate cancer in Switzerland (unspecified route) before March 2023 (NUCLIDIUM pipeline, March 2023)